Status:
COMPLETED
Development of ImmunOncoTool
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
American Cancer Society, Inc.
Bristol-Myers Squibb
Conditions:
Cancer
Cancer, Treatment-Related
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to facilitate the recognition and early management of Immune Related Adverse Events (irAEs) experienced by cancer patients taking immunotherapy. This is done through the d...
Detailed Description
Experiencing adverse events can compromise the clinical benefit of a cancer treatment, and may go undetected by clinicians. Specific to checkpoint inhibitors, Immune Related Adverse Events (irAEs) inc...
Eligibility Criteria
Inclusion
- ≥ 18 years of age
- Provider and electronic medical report (EMR) confirmed diagnosis of lung, kidney, urothelial, or melanoma cancer as checkpoint inhibitors are used primarily in these disease sites
- English-speaking as the content and website will only be available in English for feasibility testing
- Have initiated a checkpoint inhibitor
- Have access to the internet
Exclusion
- significant cognitive impairment or inpatient psychiatric treatment for severe mental illness or overt signs of severe psychopathology (e.g., psychosis)
- concurrent cancer-related treatment aside from checkpoint inhibitors
- pre-existing auto-immune condition which may impact the course of treatment.
Key Trial Info
Start Date :
December 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 17 2021
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT04513678
Start Date
December 18 2019
End Date
December 17 2021
Last Update
April 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611